Targeting B Cell Signaling in Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

Published:2017-07-28 Issue:9 Volume:19 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Arnason Jon E.,Brown Jennifer R.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s11912-017-0620-7/fulltext.html

Reference104 articles.

1. Dameshek W. Chronic lymphocytic leukemia—an accumulative disease of immunolgically incompetent lymphocytes. Blood. 1967;29(4):Suppl:566–84.

2. Rai KR. A critical analysis of staging in CLL. In: Chronic lymphocytic leukemia: recent progress and future direction. UCLA Symp Mol Cell Biol New Ser. 1987;59:253.

3. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559–66.

4. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.

5. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014;124(20):3059–64.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases;Journal of Medicinal Chemistry;2024-02-07

2. Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies;Frontiers in Oncology;2021-04-01

3. Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group;Hematological Oncology;2021-03-26

4. Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges;British Journal of Clinical Pharmacology;2020-09-15

5. Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents;Frontiers in Oncology;2020-06-25